Acute effects of repetitive hemodialysis on circulating immunoreactive parathyroid hormone levels in uremic patients undergoing vitamin D (Calcitriol) therapy

R. Bellazzi, D. Romanini, L. Bacchella, M. Nai, C. Aprile, M. Santagostino, A. De Vincenzi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The acute effects on parathyroid gland activity of repetitive hemodialysis with a dialysate calcium concentration of between 3.5 and 4 mEq/1 were evaluated in 21 hemodialysis patients on calcitriol therapy for 1 year or more. In this study circulating immunoreactive parathyroid hormone (iPTH) levels were measured using radioimmunoassay specific for C-terminal iPTH (C-PTH), middle molecule iPTH (MM-PTH) and intact iPTH (I-PTH), before the dialysis session at the end of the week (I), after 4h regular hemodialysis (II) and after a further 72 h (III). C-PTH was abnormally high (202 ± 64 pmol/l) (I) in 18 patients with no documented parathyroid hyperplasia and showed no significant difference in subsequent controls. MM-PTH was also high (379 ± 125.5 pmol/1) (I), but decreased to 348 ± l36.7 (II) (p<0.05) and returned to predialysis levels (III). I-PTH (I) was 8.2 ± 5.3 pmol/1 (normal levels in 8 patients), fell to 3.4 ± 2.6 pmol/l (II) (p <0.01), and increased (p <0.01) with respect to the basal levels of 11.1 ± 7.5 pmol/l (III). Three patients presented echographically documentable parathyroid hyperplasia and, despite constantly high iPTH levels, showed a similar I-PTH behavior while MM-PTH and C-PTH revealed no constant pattern. The decrease in iPTH levels was accompanied by a significant increase in total calcium and ionized calcium during the hemodialysis session. No significant changes in iCa and Ca together with I-PTH levels were found in 4 volunteers before and after the hemodialysis session with dialysate calcium 2.75 mEq/1. We conclude that I-PTH assay has been shown to capture acute changes in parathyroid gland activity in hemodialyzed patients for both low and high iPTH levels. High calcium dialysate hemodialysis inhibits acutely intradialytic PTH secretion but the effect is just temporary and the 72-hour interdialytic period, despite vitamin D therapy, stimulates parathyroid secretion significantly. Nevertheless, I-PTH fluctuations occur in some patients within the normal range, and high dialysate and calcitriol therapy seem to be capable of controlling parathyroid activity; as regards the remaining population, we suggest that a personalized therapeutic approach should be studied with a view to achieving a better control of interdialytic calcium homeostasis.

Original languageEnglish
Pages (from-to)273-282
Number of pages10
JournalNephron
Volume57
Issue number3
Publication statusPublished - 1991

Fingerprint

Calcitriol
Parathyroid Hormone
Vitamin D
Renal Dialysis
Dialysis Solutions
Calcium
Parathyroid Glands
Hyperplasia
Therapeutics
Radioimmunoassay
Dialysis
Volunteers
Reference Values
Homeostasis
Population

Keywords

  • calcitriol
  • dialysate calcium concentration
  • immunoreactive parathyroid hormone

ASJC Scopus subject areas

  • Nephrology

Cite this

Bellazzi, R., Romanini, D., Bacchella, L., Nai, M., Aprile, C., Santagostino, M., & De Vincenzi, A. (1991). Acute effects of repetitive hemodialysis on circulating immunoreactive parathyroid hormone levels in uremic patients undergoing vitamin D (Calcitriol) therapy. Nephron, 57(3), 273-282.

Acute effects of repetitive hemodialysis on circulating immunoreactive parathyroid hormone levels in uremic patients undergoing vitamin D (Calcitriol) therapy. / Bellazzi, R.; Romanini, D.; Bacchella, L.; Nai, M.; Aprile, C.; Santagostino, M.; De Vincenzi, A.

In: Nephron, Vol. 57, No. 3, 1991, p. 273-282.

Research output: Contribution to journalArticle

Bellazzi, R, Romanini, D, Bacchella, L, Nai, M, Aprile, C, Santagostino, M & De Vincenzi, A 1991, 'Acute effects of repetitive hemodialysis on circulating immunoreactive parathyroid hormone levels in uremic patients undergoing vitamin D (Calcitriol) therapy', Nephron, vol. 57, no. 3, pp. 273-282.
Bellazzi, R. ; Romanini, D. ; Bacchella, L. ; Nai, M. ; Aprile, C. ; Santagostino, M. ; De Vincenzi, A. / Acute effects of repetitive hemodialysis on circulating immunoreactive parathyroid hormone levels in uremic patients undergoing vitamin D (Calcitriol) therapy. In: Nephron. 1991 ; Vol. 57, No. 3. pp. 273-282.
@article{19d9f373f7e442a4b5f5711c2cfcd874,
title = "Acute effects of repetitive hemodialysis on circulating immunoreactive parathyroid hormone levels in uremic patients undergoing vitamin D (Calcitriol) therapy",
abstract = "The acute effects on parathyroid gland activity of repetitive hemodialysis with a dialysate calcium concentration of between 3.5 and 4 mEq/1 were evaluated in 21 hemodialysis patients on calcitriol therapy for 1 year or more. In this study circulating immunoreactive parathyroid hormone (iPTH) levels were measured using radioimmunoassay specific for C-terminal iPTH (C-PTH), middle molecule iPTH (MM-PTH) and intact iPTH (I-PTH), before the dialysis session at the end of the week (I), after 4h regular hemodialysis (II) and after a further 72 h (III). C-PTH was abnormally high (202 ± 64 pmol/l) (I) in 18 patients with no documented parathyroid hyperplasia and showed no significant difference in subsequent controls. MM-PTH was also high (379 ± 125.5 pmol/1) (I), but decreased to 348 ± l36.7 (II) (p<0.05) and returned to predialysis levels (III). I-PTH (I) was 8.2 ± 5.3 pmol/1 (normal levels in 8 patients), fell to 3.4 ± 2.6 pmol/l (II) (p <0.01), and increased (p <0.01) with respect to the basal levels of 11.1 ± 7.5 pmol/l (III). Three patients presented echographically documentable parathyroid hyperplasia and, despite constantly high iPTH levels, showed a similar I-PTH behavior while MM-PTH and C-PTH revealed no constant pattern. The decrease in iPTH levels was accompanied by a significant increase in total calcium and ionized calcium during the hemodialysis session. No significant changes in iCa and Ca together with I-PTH levels were found in 4 volunteers before and after the hemodialysis session with dialysate calcium 2.75 mEq/1. We conclude that I-PTH assay has been shown to capture acute changes in parathyroid gland activity in hemodialyzed patients for both low and high iPTH levels. High calcium dialysate hemodialysis inhibits acutely intradialytic PTH secretion but the effect is just temporary and the 72-hour interdialytic period, despite vitamin D therapy, stimulates parathyroid secretion significantly. Nevertheless, I-PTH fluctuations occur in some patients within the normal range, and high dialysate and calcitriol therapy seem to be capable of controlling parathyroid activity; as regards the remaining population, we suggest that a personalized therapeutic approach should be studied with a view to achieving a better control of interdialytic calcium homeostasis.",
keywords = "calcitriol, dialysate calcium concentration, immunoreactive parathyroid hormone",
author = "R. Bellazzi and D. Romanini and L. Bacchella and M. Nai and C. Aprile and M. Santagostino and {De Vincenzi}, A.",
year = "1991",
language = "English",
volume = "57",
pages = "273--282",
journal = "Experimental Nephrology",
issn = "0028-2766",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Acute effects of repetitive hemodialysis on circulating immunoreactive parathyroid hormone levels in uremic patients undergoing vitamin D (Calcitriol) therapy

AU - Bellazzi, R.

AU - Romanini, D.

AU - Bacchella, L.

AU - Nai, M.

AU - Aprile, C.

AU - Santagostino, M.

AU - De Vincenzi, A.

PY - 1991

Y1 - 1991

N2 - The acute effects on parathyroid gland activity of repetitive hemodialysis with a dialysate calcium concentration of between 3.5 and 4 mEq/1 were evaluated in 21 hemodialysis patients on calcitriol therapy for 1 year or more. In this study circulating immunoreactive parathyroid hormone (iPTH) levels were measured using radioimmunoassay specific for C-terminal iPTH (C-PTH), middle molecule iPTH (MM-PTH) and intact iPTH (I-PTH), before the dialysis session at the end of the week (I), after 4h regular hemodialysis (II) and after a further 72 h (III). C-PTH was abnormally high (202 ± 64 pmol/l) (I) in 18 patients with no documented parathyroid hyperplasia and showed no significant difference in subsequent controls. MM-PTH was also high (379 ± 125.5 pmol/1) (I), but decreased to 348 ± l36.7 (II) (p<0.05) and returned to predialysis levels (III). I-PTH (I) was 8.2 ± 5.3 pmol/1 (normal levels in 8 patients), fell to 3.4 ± 2.6 pmol/l (II) (p <0.01), and increased (p <0.01) with respect to the basal levels of 11.1 ± 7.5 pmol/l (III). Three patients presented echographically documentable parathyroid hyperplasia and, despite constantly high iPTH levels, showed a similar I-PTH behavior while MM-PTH and C-PTH revealed no constant pattern. The decrease in iPTH levels was accompanied by a significant increase in total calcium and ionized calcium during the hemodialysis session. No significant changes in iCa and Ca together with I-PTH levels were found in 4 volunteers before and after the hemodialysis session with dialysate calcium 2.75 mEq/1. We conclude that I-PTH assay has been shown to capture acute changes in parathyroid gland activity in hemodialyzed patients for both low and high iPTH levels. High calcium dialysate hemodialysis inhibits acutely intradialytic PTH secretion but the effect is just temporary and the 72-hour interdialytic period, despite vitamin D therapy, stimulates parathyroid secretion significantly. Nevertheless, I-PTH fluctuations occur in some patients within the normal range, and high dialysate and calcitriol therapy seem to be capable of controlling parathyroid activity; as regards the remaining population, we suggest that a personalized therapeutic approach should be studied with a view to achieving a better control of interdialytic calcium homeostasis.

AB - The acute effects on parathyroid gland activity of repetitive hemodialysis with a dialysate calcium concentration of between 3.5 and 4 mEq/1 were evaluated in 21 hemodialysis patients on calcitriol therapy for 1 year or more. In this study circulating immunoreactive parathyroid hormone (iPTH) levels were measured using radioimmunoassay specific for C-terminal iPTH (C-PTH), middle molecule iPTH (MM-PTH) and intact iPTH (I-PTH), before the dialysis session at the end of the week (I), after 4h regular hemodialysis (II) and after a further 72 h (III). C-PTH was abnormally high (202 ± 64 pmol/l) (I) in 18 patients with no documented parathyroid hyperplasia and showed no significant difference in subsequent controls. MM-PTH was also high (379 ± 125.5 pmol/1) (I), but decreased to 348 ± l36.7 (II) (p<0.05) and returned to predialysis levels (III). I-PTH (I) was 8.2 ± 5.3 pmol/1 (normal levels in 8 patients), fell to 3.4 ± 2.6 pmol/l (II) (p <0.01), and increased (p <0.01) with respect to the basal levels of 11.1 ± 7.5 pmol/l (III). Three patients presented echographically documentable parathyroid hyperplasia and, despite constantly high iPTH levels, showed a similar I-PTH behavior while MM-PTH and C-PTH revealed no constant pattern. The decrease in iPTH levels was accompanied by a significant increase in total calcium and ionized calcium during the hemodialysis session. No significant changes in iCa and Ca together with I-PTH levels were found in 4 volunteers before and after the hemodialysis session with dialysate calcium 2.75 mEq/1. We conclude that I-PTH assay has been shown to capture acute changes in parathyroid gland activity in hemodialyzed patients for both low and high iPTH levels. High calcium dialysate hemodialysis inhibits acutely intradialytic PTH secretion but the effect is just temporary and the 72-hour interdialytic period, despite vitamin D therapy, stimulates parathyroid secretion significantly. Nevertheless, I-PTH fluctuations occur in some patients within the normal range, and high dialysate and calcitriol therapy seem to be capable of controlling parathyroid activity; as regards the remaining population, we suggest that a personalized therapeutic approach should be studied with a view to achieving a better control of interdialytic calcium homeostasis.

KW - calcitriol

KW - dialysate calcium concentration

KW - immunoreactive parathyroid hormone

UR - http://www.scopus.com/inward/record.url?scp=0026032965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026032965&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 273

EP - 282

JO - Experimental Nephrology

JF - Experimental Nephrology

SN - 0028-2766

IS - 3

ER -